Erythropoietin, iron, and erythropoiesis

Blood

Volumn 96, Issue 3, 2000, Pages 823-833

  Goodnough, L T ^a   Skikne, B ^a   Brugnara, C ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; FERRITIN; IRON; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN RECEPTOR;

ANEMIA; BLEEDING; ERYTHROPOIESIS; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HUMAN; IRON STORAGE; IRON THERAPY; PRIORITY JOURNAL; REVIEW;

EID: 0034254356     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.3.823.015k49_823_833     Document Type: Review

References (187)

1. Erythropoiesis, erythropoietin, and iron
2. The metabolism of hemoglobin and bile pigment in hemolytic disease
3. Control of marrow production by the level of iron supply
4. Treatment of haemochromatosis by energetic phlebotomy: One patient's response to the letting of 55 liters of blood in 11 months
5. Rate of regeneration after blood loss
6. Perspectives in iron metabolism
7. Limitations of the erythropoietic response to serial phlebotomy. Implications for autologous blood predeposit programs
8. Effect of repeated whole blood donations on serum immunoreactive erythropoietin levels in autologous donors
9. Compensatory erythropoiesis during routine autologous blood donation
10. Preoperative red cell production in patients undergoing weekly autologous blood donation
11. Efficacy of oral iron supplementation is not enhanced by additional intravenous iron during autologous blood donation
12. Oral or intravenous iron as an adjunct to autologous blood donation in elective surgery: A randomized, controlled study
13. Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy
14. Preoperative red blood cell production in patients undergoing aggressive autologous blood phlebotomy with and without erythropoietin therapy
15. A phase III trial of recombinant human erythropoietin therapy in non- anemic orthopedic patients subjected to aggressive autologous blood phlebotomy: Dose, response, toxicity, efficacy
16. A standardized method for calculating blood loss
17. Red blood cell volume in autologous and homologous blood units: Implications for risk benefit assessment for autologous blood 'crossover' and directed blood transfusion
18. Erythropoietin response to anaemia is not altered by surgery or recombinant human erythropoietin therapy
19. The erythropoietin/hematocrit relationship in normal and polycythemic man: Implications of marrow regulation
20. Effectiveness of very low doses of subcutaneous recombinant human erythropoietin in facilitating autologous blood donation before orthopedic surgery
21. Epoietin alfa in low hematocrit patients to facilitate autologous blood donation in total hip replacement: A randomized, double-blind, placebo- controlled, dose-ranging study
22. Red blood cell regeneration induced by subcutaneous recombinant erythropoietin: Iron-deficient erythropoiesis in iron-replete subjects
23. The effect of patient size and dose of recombinant human erythropoietin therapy on red blood cell expansion
24. The endogenous erythropoietin response and the erythropoietic response to blood loss anemia: The effects of age and gender
25. Use of erythropoietin to increase the volume of autologous blood donated by orthopedic patients
26. The effect of recombinant human erythropoietin on the efficacy of autologous blood donation in patients with low hematocrits: A multicenter, randomized, double-blind, controlled trial
27. Comparison of efficacy of oral versus intravenous iron supplementation with epoietin alfa treatment in arthroplasty patients
28. The erythropoietic response to erythropoietin therapy in patients with rheumatoid arthritis
29. Comparison between intravenous and subcutaneous recombinant human erythropoietin (epoietin alfa) administration in presurgical autologous blood donation in anemic rheumatoid arthritis patients undergoing major orthopedic surgey
30. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease
31. Erythropoiesis in iron-depleted and iron-replete patients stimulated with erythropoietin: The relevance of storage iron
32. The effect of oral iron supplementation on erythropoiesis in autologous blood donors
33. Effect of enhanced erythropoiesis on iron absorption
34. Peri-surgical erythropoietin application in anemic patients with colorectal cancer: A double-blind randomized study
35. Erythropoietic activity and iron metabolism in autologous blood donors during recombinant human erythropoietin therapy
36. Erythropoietin in renal and non-renal anemia
37. Erythropoietin receptors on murine erythroid colony-forming units: Natural history
38. Quantitation of specific binding of erythropoietin to human erythroid colony-forming cells
39. Pharmacokinetics and pharmaco dynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects
40. Efficacy of different dosing regimens for recombinant human erythropoietin in a simulated persurgical setting: The importance of iron availability in optimizing response
41. Optimal timing of repeated rherythropoietin administration improves its effectiveness in stimulating erythropoiesis in healthy volunteers
42. Quantitative assessment of erythropoiesis in haemodialysis patients demonstrates gradual expansion of erythroblasts during constant treatment with recombinant human erythropoietin
43. Novel erythropoiesis stimulating protein (NESP) maintains hemoglobin in ESRD patients when administered once weekly or once every other week
44. Erythropoiesis in response to blood loss in man
45. 59 oxide in red cell formation
46. The metabolism of iron dextran given as a total dose infusion to iron deficient Jamaican subjects
47. The measurement of reticuloendothelial iron release using iron-dextran
48. The effect of intravenous iron on the reticulocyte response to recombinant human erythropoietin
49. Primum non nocere
50. Intravenous iron dextran therapy in the treatment of anemia occurring in surgical, gynecologic, and obstetric patients
51. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation
52. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis
53. Clinical practice guidelines for the treatment of anemia of chronic renal failure
54. Intravenous iron and erythropoietin for anemia associated with Crohn's disease
55. Correction of anemia of end-stage renal disease with recombinant human erythropoietin
56. Anemia in hemodialysis patients: Variables affecting this outcome predictor
57. Commentary: An anemia of chronic disease, after all?
58. Erythropoietin hyporesponsiveness: From iron deficiency to iron overload
59. Effects of recombinant human erthropoietin on iron absorption in chronic renal failure
60. Effect of enhanced erythropoiesis on iron absorption
61. Efficiency of oral iron therapy in patients receiving recombinant human erythropoietin
62. The effects of normal as compared to low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin
63. Erythropoietin for end-stage renal disease
64. Regular, low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients
65. Regulation of cellular iron metabolism by erythropoietin: Activation of iron-regulatory protein and up regulation transferrin receptor expression in erythroid cells
66. Iron overload in renal failure patients: Changes since the introduction of erythropoietin therapy
67. Iron and anemia of chronic disease
68. Serum transferrin receptor: A quantitative measure of tissue iron deficiency
69. Serum ferritin as a measure of iron stores in normal subjects
70. Adequacy of supply for erythropoiesis: In vivo observations in humans
71. Iron-restricted erythropoiesis as a limitation to autologous blood donation in the erythropoietin-stimulated bone marrow
72. Laboratory tests of iron status: Correlation or common sense?
73. Disorders of iron metabolism diagnostic methods
74. Pediatric reference ranges for creatine kinase, CKMB, troponin I, iron and cortisol
75. Serum iron: Would analytical improvement enhance patient outcome?
76. When is a serum iron really a serum iron? The status of serum iron measurements
77. The relation between chemically measured total iron-binding capacity concentrations and immunologically measured transferrin concentrations in human serum
78. Assessment of bone marrow and body iron stores: Old techniques and new technologies
79. Serum ferritin measurement and the degree of agreement using four techniques
80. A clinical evaluation of serum ferritin as an index of iron stores
81. Iron-chelation therapy with oral deferiprone in patients with thalassemia major
82. Iron-chelating therapy and the treatment of thalassemia
83. The effect of erythroid hyperplasia on iron balance
84. Screening for iron deficiency: An analysis based on bone-marrow examinations and serum ferritin determinations in a population sample of women
85. Factors affecting the concentrations of ferritin in serum in a healthy Australian population
86. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency
87. Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations
88. Effects of subcutaneous recombinant human erythropoietin in normal subjects: Development of decreased reticulocyte hemoglobin content and iron- deficient erythropoiesis
89. Subcutaneous compared with intravenous epoietin in patients receiving hemodialysis
90. Prediction of response to erythropoietin treatment in chronic anemia of cancer
91. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin lymphoma: Dose finding and identification of predictors of response
92. Prediction of response to recombinant human erythropoietin (r- HuEPO/Epoetin-a) therapy in cancer patients
93. Recombinant human erythropoietin in the treatment of cancer-related anemia
94. Evaluation of bone marrow iron stores in anemia associated with chronic disease: A comparative study of serum and red cell ferritin
95. Is basic red cell ferritin a more specific indicator than serum ferritin in the assessment of iron stores in the elderly?
96. Erythrocyte ferritin in patients on chronic hemodialysis treatment
97. Assessment of iron status by erythrocyte ferritin in uremic patients with or without recombinant human erythropoietin therapy
98. The use of zinc protoporphyrin in screening young children for iron deficiency
99. Washing erythrocytes to remove interferents in measurements of zinc protoporphyrin by front-face hematofluorometry
100. Zinc protoporphyrin and iron-deficient erythropoiesis
101. Detection of functional iron deficiency during erythropoietin treatment a new approach
102. Monitoring of iron status and iron supplementation in patients treated with erythropoietin
103. Meeting the challenges of a new millennium: Optimizing the use of recombinant human erythropoietin
104. Iron monitoring and supplementation: How do we achieve the best results?
105. Percentage of hypochromic red blood cells as predictor of erythropoietic and iron response after i.v. iron supplementation in maintenance haemodialysis patients
106. Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients
107. What is the most appropriate strategy to monitor functional iron deficiency in the dialysed patient on rhEPO therapy? Measurement of hypochromic red blood cells is not the first line procedure to identify the patient with iron deficiency
108. The effect of red cell shape on the measurement of red cell volume: A proposed method for the comparative assessment of this effect among various haematological analysers
109. Rherythropoietin stimulates immature reticulocyte release in man
110. Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy
111. Use of recombinant human erythropoietin outside the setting of uremia
112. Automated reticulocyte counting and measurement of reticulocyte cellular indices: Evaluation of the Miles H*3 blood analyzer
113. Laboratory evaluation of the Miles H*3 automated reticulocyte counter: A comparative study with manual reference method and Sysmex R-1000
114. Simultaneous measurement of reticulocyte and red blood cell indices in healthy subjects and patients with microcytic and macrocytic anemia
115. Use of reticulocyte cellular indices in the diagnosis and treatment of hematological disorders
116. Reticulocyte hemoglobin: An integrated parameter for evaluation of erythropoietic activity
117. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO
118. Evaluation of RBC ferritin and reticulocyte measurements in monitoring response to intravenous iron therapy
119. Reticulocyte indices in patients with end stage renal disease on hemodialysis
120. Utility of flow cytometric reticulocyte quantification as a predictor of engraftment in autologous bone marrow transplantation
121. Kinetics of reticulocyte maturity fractions and indices and iron status during therapy with epoetin beta (recombinant human erythropoietin) in cardiac surgery patients
122. Reticulocyte hemoglobin content to diagnose iron deficiency in children
123. Interference of blood leucocytes in the measurements of immature red cells (reticulocytes) by two different semi-automated flow cytometry technologies
124. Flow cytometric reticulocyte analysis: Multiinstitutional interlaboratory correlation study
125. Report on the ISLH-sponsored immature reticulocyte fraction (IRF) workshop
126. Recombinant human erythropoietin In autologous blood donors: A dose- finding study
127. Modifications of erythropoiesis in myelodysplastic syndromes treated with recombinant erythropoietin as evaluated by soluble transferrin receptor, high fluorescence reticulocytes arid hypochromic erythrocytes
128. The clinical measurement of serum transferrin receptor
129. Serum transferrin receptor as a new index of erythropoiesis
130. Serum transferrin receptor and transferrin receptor-ferritin index identify healthy subjects with subclinical iron deficits
131. Serum transferrin receptor distinguishes the anemia of chronic disease from iron deficiency anemia
132. Evaluation of new immunoenzymometric assay for measuring soluble transferrin receptor to detect iron deficiency in anemic patients
133. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis
134. Early prediction of response to recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibrinogen
135. Serum transferrin receptor
136. Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure
137. Circulating transferrin receptor assay - Coming of age
138. Erythropoietin
139. Erythropoietin
140. Inadequate erythropoietin response to anemia: Definition and clinical relevance
141. Decreased erythropoetin response in patients with the anemia of cancer
142. Serum immuno reactive erythropoietin in HIV-infected patients
143. Blunted erythropoietin response to anemia in rheumatoid arthritis
144. Effects of recombinant human erythropoietin combined with granulocyte macrophage colony-stimulating factor in the treatment of patients with myeloplastic syndrome
145. Erythropoieitin treatment of anemia assocated with multiple myeloma
146. Multicenter study of recombinant human erythropoietin in correction of anemia in patients with rheumatoid arthritis
147. Recombinant human erythropoietin for the treatment of the anemia of cancer
148. Impact of therapy with erythropoietin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice
149. Does baseline endogenous erythropoietin level impact hemoglobin (Hb) response to rHuEPO in cancer patients [abstract]?
150. Red blood cell precursor mass as an independent determinant of serum erythropoietin level
151. Influence of body iron stores on the serum erythropoietin concentration in hemodialyzed patients
152. The effect of hemolysates on red cell production and erythropoietin release
153. Marked erythropoietin increase before fall in hemoglobin after treatment with cytostatic drugs suggests mechanism other than anaemia for stimulation
154. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset, juvenile chronic arthritis
155. Anemia in children with cancer is associated with decreased erythropoietic activity and not with inadequate erythropoietin production
156. Progress in understanding the pathogenesis of the anemia of chronic disease
157. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production
158. Evidence-based recommendations for the clinical use of recombinant human erythropoietin
159. Clinical use of the total dose intravenous of iron dextran
160. Intravenous iron dextran in clinical medicine
161. A surveillance program on a long-established product: Imferon (iron dextran BP)
162. The safety of intravenous iron dextran in hemodialysis patients
163. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients
164. Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextran
165. Safety aspects of parenteral iron in patients with end-stage renal disease
166. Intravenous ferric saccharate as an iron supplementation in dialysis patients
167. Importance of iron supply for erythropoietin therapy
168. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American trial
169. Intravenous administration of iron gluconate during haemodialysis
170. Serious adverse reactions after intravenous ferric gluconate
171. 'Over saturation' of transferrin after intravenous ferric gluconate (Ferrlecit) in haemodialysis patients
172. Comparison of methods used to measure serum iron in the presence of iron gluconate or iron dextran
173. Characteristics of iron dextran utilization in man
174. Erythropoietin therapy
175. Consensus statement: Using epoietin alfa to decrease the risk of allogeneic blood transfusion in the surgical setting
176. A safety and efficacy comparison study of two dosing regiments of erythropoietin alfa in patients undergoing major orthopedic surgery
177. The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having a major orthopaedic operation
178. Biotechnology - The enormous cost of success
179. Economic analysis of erythropoietin use in orthopaedic surgery
180. Critical role of iron overload in the increased susceptibility of haemodialysis patients to bacterial infections: Beneficial effects of desferrioxamine
181. Risk factors for bacterial infections in chronic haemo-dialysis adult patients: A multicenter prospective survey
182. Frequent IV iron dosing is associated with higher infectious deaths
183. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men
184. Body iron stores and the risk of coronary heart disease
185. Relationship between serum ferritin and risk factors for ischaemic heart disease in 2235 Danes aged 30-60 years
186. Intravenous iron supplementation in end-stage renal disease patients